MP
Manning Paul B Director
Board M
US US · SEC (Form 4)
Explore the full record of transactions filed by Manning Paul B, Director. Director active across 6 companies, notably Taysha Gene Therapies, Inc.. Cumulatively, 20 disclosures have been recorded. Total volume traded: €4.5m. The latest transaction was filed on 31 March 2022 — Attribution. Regulator: SEC (Form 4). All data is accessible without signup.
Declarations 20 total
0435,674 shares 0
Common Stock
SEC:0001104659-22-047871:0 · 31 Mar 2022
€2m 392,156 shares @ €4.7302 0.037% mcap 100.0% of flow
Common Stock
SEC:0001104659-22-047360:0 · 18 Apr 2022
Ideal exit: 13 Jan 2023 (T+270) €399,735 58,000 shares @ €6.892 0.023% mcap 26.5% of flow
Common Stock
SEC:0001209191-22-007126:0 · 2 Feb 2022
Ideal exit: 30 Oct 2022 (T+270) €399,735 58,000 shares @ €6.892 0.023% mcap 61.6% of flow
Common Stock
SEC:0001209191-22-007126 · 2 Feb 2022
Ideal exit: 30 Oct 2022 (T+270) €250,644 30,023 shares @ €8.3484 100.0% of flow
Common Stock
SEC:0001209191-21-068031 · 2 Dec 2021
Ideal exit: 29 Aug 2022 (T+270) €250,644 30,023 shares @ €8.3484 0.23% mcap 50.0% of flow
Common Stock
SEC:0001209191-21-068031:0 · 2 Dec 2021
Ideal exit: 29 Aug 2022 (T+270) €25,829 2,202 shares @ €11.7297 4.0% of flow
Common Stock
SEC:0001209191-21-067005 · 24 Nov 2021
Ideal exit: 21 Aug 2022 (T+270) €25,829 2,202 shares @ €11.7297 0.0015% mcap 1.7% of flow
Common Stock
SEC:0001209191-21-067005:0 · 24 Nov 2021
Ideal exit: 21 Aug 2022 (T+270) €223,089 20,000 shares @ €11.1545 34.4% of flow
Common Stock
SEC:0001209191-21-066702 · 23 Nov 2021
Ideal exit: 20 Aug 2022 (T+270) €223,089 20,000 shares @ €11.1545 0.013% mcap 14.8% of flow
Common Stock
SEC:0001209191-21-066702:0 · 23 Nov 2021
Ideal exit: 20 Aug 2022 (T+270) 679,158 shares
Common Stock
SEC:0000899243-21-031614 · 29 Jul 2021
679,158 shares
Common Stock
SEC:0000899243-21-031614:0 · 29 Jul 2021
679,158 shares
Common Stock
SEC:0000899243-21-031096 · 29 Jul 2021
679,158 shares
Common Stock
SEC:0000899243-21-031096:0 · 29 Jul 2021
€223,997 36,000 shares @ €6.2221 100.0% of flow
Common Stock
SEC:0000899243-21-030774 · 27 Jul 2021
Ideal exit: 23 Apr 2022 (T+270) €223,997 36,000 shares @ €6.2221 0.072% mcap 50.0% of flow
Common Stock
SEC:0000899243-21-030774:0 · 27 Jul 2021
Ideal exit: 23 Apr 2022 (T+270) 2,950,484 shares
Common Stock
SEC:0001209191-21-046042 · 6 Jul 2021
2,950,484 shares
Common Stock
SEC:0001209191-21-046042:0 · 6 Jul 2021
€208,457 12,000 shares @ €17.3714 100.0% of flow
Common Stock
SEC:0001209191-21-033009 · 14 May 2021
Ideal exit: 8 Feb 2022 (T+270) €208,457 12,000 shares @ €17.3714 0.012% mcap 13.8% of flow
Common Stock
SEC:0001209191-21-033009:0 · 14 May 2021
Ideal exit: 8 Feb 2022 (T+270) About Manning Paul B Manning Paul B is an executive at Taysha Gene Therapies, Inc.